hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06297434, orgStudyIdInfo id: JH-221-201, briefTitle: Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-15, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: J2H Biotech, class: INDUSTRY, descriptionModule briefSummary: The study aims to evaluate the safety of J2H-1702 compared to the placebo and explore the efficacy of J2H-1702 at Week 12 timepoint after administration compared to baseline in patients with NASH., conditionsModule conditions: Non-alcoholic Steatohepatitis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: J2H-1702, interventions name: J2H-1702, interventions name: J2H-1702, interventions name: Placebo, outcomesModule primaryOutcomes measure: Changes from baseline in results on MRI-PDFF at week12., primaryOutcomes measure: Changes from baseline in results on MRE at week12., eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: J2H Biotech, status: RECRUITING, city: Suwon, state: Gyeonggi-do, zip: 16684, country: Korea, Republic of, contacts name: Eunji Byeon, role: CONTACT, geoPoint lat: 37.29111, lon: 127.00889, hasResults: False
protocolSection identificationModule nctId: NCT06297421, orgStudyIdInfo id: SZYY20240229IBS-D, briefTitle: Efficacy and Safety of FMT for the Treatment of IBS-D and Mental Health Comorbidity in Young Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2026-01, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Shenzhen Hospital of Southern Medical University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy and safety of Fecal Microbiota Transplantation compared with placebo in the treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) and Mental Health Comorbidity in Young Adults., conditionsModule conditions: Irritable Bowel Syndrome With Diarrhea, conditions: Fecal Microbiota Transplantation, conditions: Mental Health Issue, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 434, type: ESTIMATED, armsInterventionsModule interventions name: Fecal Microbiota Transplantation, interventions name: Placebo, outcomesModule primaryOutcomes measure: Percentage of Patients Who Were Composite Weekly Responders, primaryOutcomes measure: Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0, secondaryOutcomes measure: Percentage of Patients Who Were Composite Weekly Responders, secondaryOutcomes measure: Percentage of Patients Who Were Abdominal Pain Weekly Responder, secondaryOutcomes measure: Percentage of Patients Who Were Stool Consistency Weekly Responder, secondaryOutcomes measure: Percentage of Patients Who Were Abdominal Bloating Weekly Responder, secondaryOutcomes measure: Percentage of Participants Who Were Responders in IBS Symptoms Relief Scale, secondaryOutcomes measure: Change from Baseline in the Weekly Average of Worst Abdominal Pain in the Past 24 hours, secondaryOutcomes measure: Change from Baseline in the Number of Days per Week with at Least One Stool with Consistency of Type 6 or 7, secondaryOutcomes measure: Change from Baseline in the Number of Stools of Type 6 or 7 per Week, secondaryOutcomes measure: Change from Baseline in the Weekly Average of Worst Abdominal Bloating in the Past 24 Hours Score, secondaryOutcomes measure: Change from baseline in Irritable Bowel Syndrome Severity Scale (IBS-SSS) Scores, secondaryOutcomes measure: Change from baseline in Irritable Bowel Syndrome Quality of Life Scale (IBS-QoL) Total Scores, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 25 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shenzhen Hospital of Southern Medical University, city: Shenzhen, state: Guangdong, zip: 518000, country: China, geoPoint lat: 22.54554, lon: 114.0683, hasResults: False
protocolSection identificationModule nctId: NCT06297408, orgStudyIdInfo id: JWCAR029115, briefTitle: Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Shanghai Ming Ju Biotechnology Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To assess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China., conditionsModule conditions: Systemic Lupus Erythematosus, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Relma-cel, outcomesModule primaryOutcomes measure: DLT rate, primaryOutcomes measure: determine RP2D, secondaryOutcomes measure: SELENA-SLEDAI, secondaryOutcomes measure: BILAG -2004, secondaryOutcomes measure: PGA (physician global assessment) score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06297395, orgStudyIdInfo id: Cervical Traumatic Inj, briefTitle: Subaxial Cervical Traumatic Injuries, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The aim of this study is to assess the mid-term outcomes of treating subaxial cervical traumatic injury cases admitted to the Trauma Unit of Assiut University Hospital., conditionsModule conditions: Cervical Injury Spine, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: OTHER, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Percentage of improvement, secondaryOutcomes measure: Patient Outcomes, secondaryOutcomes measure: Complication, secondaryOutcomes measure: rehabilitation, secondaryOutcomes measure: Complication, secondaryOutcomes measure: rehabilitation, secondaryOutcomes measure: Complication, secondaryOutcomes measure: Complication, secondaryOutcomes measure: Complication, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06297382, orgStudyIdInfo id: SBU-HEM-PSI-01, briefTitle: Impact of ChatGPT-based Nursing Process Training, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-06, primaryCompletionDateStruct date: 2024-04-24, completionDateStruct date: 2025-04-25, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Saglik Bilimleri Universitesi, class: OTHER, descriptionModule briefSummary: The goal of this randomized controlled study is to determine the impact of ChatGPT based nursing process training on nursing students' clinical decision-making competencies and artificial intelligence anxiety.Population and Sample: The population of the research consists of senior students studying at Gülhane Faculty of Nursing, University of Health Sciences. Power analysis was performed to determine the number of people to be included in the study. The power of the test was calculated with the G\*Power 3.1 program. In a similar study in the relevant literature, the effect size regarding the change in clinical decision-making level was calculated as 0.898. In order to exceed the 99% value in determining the power of the study; At the 5% significance level and 0.898 effect size, 44 people, 22 people in the groups, need to be reached (df=21; t=1.721). In the research, it was aimed to reach a total of 60 people, 30 people in the groups, considering the high power of the test and the losses., conditionsModule conditions: Nurse-Patient Relations, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This research will be conducted as an experimental study with pretest-posttest randomised control group design., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: Experimental and control groups will be determined using https:// www.randomizer.org., whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: ChatGPT Based Nursing Process Training, outcomesModule primaryOutcomes measure: Descriptive Information Form, primaryOutcomes measure: Clinical Decision Making Scale in Nursing, primaryOutcomes measure: rtificial Intelligence Anxiety Scale:, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06297369, orgStudyIdInfo id: RHDIRB2020110301 REC #250, briefTitle: Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-08-01, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients, conditionsModule conditions: Cisplatin Adverse Reaction, conditions: Cisplatin Nephrotoxicity, conditions: Cisplatin Induced Peripheral Neuropathy, conditions: Cancer Patients, conditions: Cisplatin Ototoxicity, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: N acetyl cysteine, outcomesModule primaryOutcomes measure: The occurrence of cisplatin-induced ototoxicity in the form of hearing loss., secondaryOutcomes measure: The occurrence of cisplatin-induced nephrotoxicity., secondaryOutcomes measure: The occurrence of cisplatin-induced peripheral neuropathy., secondaryOutcomes measure: The occurrence of cisplatin-induced peripheral neuropathy., secondaryOutcomes measure: The occurrence of cisplatin-induced peripheral neuropathy., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Clinical Oncology and Nuclear Medicine, Ain Shams University Hospitals, Cairo, Egypt., status: RECRUITING, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06297356, orgStudyIdInfo id: YCEYHAN, briefTitle: The Effect of Stress Ball Utilisation on Treatment Duration, Dyspnea Severity and Anxiety Level in Nebuliser Therapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-02-19, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Kirsehir Ahi Evran Universitesi, class: OTHER, descriptionModule briefSummary: Nebul Therapy is very effective in quickly improving the symptoms of respiratory system diseases. While applying this treatment, patients are expected to complete a sufficient period of time. However, this waiting and the symptoms of the disease may cause anxiety in the patient.The aim of the study was to enable patients to spend their nebul period actively by using a stress ball. Thus, it was thought that it would make a positive contribution to dyspnea severity and anxiety levels.The main questions it aims to answer are:Does using a stress ball contribute positively to nebulizer usage time? Is the use of a stress ball effective in reducing the severity of dyspnea? Is using a stress ball effective in reducing anxiety levels?For this purpose, participants will be asked to tighten and loosen the stress ball with one hand during the nebuliser therapy.They will be expected to continue this with at least two nebuliser therapy per day. A control group will be used to determine the effectiveness of the stress ball. This group will not use a stress ball while receiving nebulizer treatment., conditionsModule conditions: Inhalation Therapy; Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized controlled trial, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Stress ball, outcomesModule primaryOutcomes measure: dyspnea severity, primaryOutcomes measure: anxiety levels, primaryOutcomes measure: treatment duration, secondaryOutcomes measure: Vital signs: Respiratory rate, secondaryOutcomes measure: Vital signs: Pulse, secondaryOutcomes measure: Vital signs: Blood pressure, secondaryOutcomes measure: saturation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yasemin CEYHAN, status: RECRUITING, city: Kırşehir, state: Center, zip: 40100, country: Turkey, contacts name: Yasemin CEYHAN, PhD, role: CONTACT, phone: +9054645898065, email: yasemin-ceyhan@hotmail.com, contacts role: CONTACT, phoneExt: CEYHAN, email: yasemin-ceyhan@hotmail.com, contacts name: Yasemin CEYHAN, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.14583, lon: 34.16389, hasResults: False
protocolSection identificationModule nctId: NCT06297343, orgStudyIdInfo id: 2023-A02491-44, briefTitle: Study of the Risk of Ischaemia Following the Creation of an Arteriovenous Fistula, acronym: MODIFVASC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: GCS Ramsay Santé pour l'Enseignement et la Recherche, class: OTHER, descriptionModule briefSummary: The purpose of this study is to identify functional vascular changes and clinical factors correlated with the occurrence of short- or medium-term hand ischaemia after arteriovenous fistula creation., conditionsModule conditions: Renal Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 544, type: ESTIMATED, armsInterventionsModule interventions name: Creation of an arteriovenous fistula, outcomesModule primaryOutcomes measure: Occurrence of ischaemia of the hand, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hôpital Privé des Peupliers, city: Paris, zip: 75013, country: France, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06297317, orgStudyIdInfo id: Trailstiff, briefTitle: Longitudinal Changes in Achilles Tendon and Medial Gastrocnemius Muscle Architecture During a 156-km Ultradistance Trail Running Event, acronym: Trailstiff, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-11-11, primaryCompletionDateStruct date: 2021-11-13, completionDateStruct date: 2024-02-01, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: University Hospital, Caen, class: OTHER, descriptionModule briefSummary: This study aimed to assess the longitudinal changes in triceps surae muscle-tendon architecture to an ultra distance trail running. Experienced trail runners (N=55, 78% men, age: 45.2 \[13.5\] years) participated in a 156-km trail run (6000m climbing) consisting in six 26-km laps. The resting architectural properties of triceps surae muscle-tendon were measured using ultrasound imaging for Achille tendon cross-sectional area (AT CSA), medial gastrocnemius muscle pennation angle, thickness, length and fiber length. Measurements were performed the day before the race (Baseline), at 52-km (T1), at 104-km (T2), at 156-km (T3) and 12 hours after the race (H12)., conditionsModule conditions: Achilles Tendinopathy, conditions: Calf Injury, conditions: Sport Injury, conditions: Lower Limb Injury, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 55, type: ACTUAL, armsInterventionsModule interventions name: Ultrasound measurement of triceps surae muscle-tendon architecture, outcomesModule primaryOutcomes measure: Achille tendon cross sectional area, primaryOutcomes measure: Medial gastrocnemius thickness, primaryOutcomes measure: Medial gastrocnemius pennation angle, primaryOutcomes measure: Medial gastrocnemius fascicle length, primaryOutcomes measure: Medial gastrocnemius muscle length, secondaryOutcomes measure: Finisher status, secondaryOutcomes measure: Average speed, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU Caen Normandie, city: Caen, zip: 14000, country: France, geoPoint lat: 49.18585, lon: -0.35912, hasResults: False
protocolSection identificationModule nctId: NCT06297291, orgStudyIdInfo id: CLN0984, briefTitle: Global Paradise System US Post Approval Study, acronym: US GPS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-09, completionDateStruct date: 2031-07, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: ReCor Medical, Inc., class: INDUSTRY, descriptionModule briefSummary: The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure., conditionsModule conditions: Hypertension, conditions: Cardiovascular Diseases, conditions: Vascular Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Paradise Ultrasound Renal Denervation Treatment, outcomesModule primaryOutcomes measure: Co-Primary Endpoint #1: Group Mean BP reduction, primaryOutcomes measure: Co-Primary Endpoint #2: Subject Responder, secondaryOutcomes measure: Change in mean home systolic/diastolic BP in mmHg, secondaryOutcomes measure: Change in mean office systolic/diastolic BP in mmHg, secondaryOutcomes measure: Change in home and office pulse pressure, secondaryOutcomes measure: Change in the number and/or dosage and/or type of antihypertensive medications taken, secondaryOutcomes measure: Change in patient reported outcomes, secondaryOutcomes measure: Percentage of patients who are controlled as measured by various cut points of home BP (control to be assessed as both < 130 mmHg systolic and <135 mmHg systolic) office BP (control to also be assessed as <130 mmHg and <140 mmHg systolic), secondaryOutcomes measure: Percentage of patients who demonstrate a reduction in home systolic BP of ≥ 5mmHg, ≥ 10 mmHg and ≥ 15 mmHg, secondaryOutcomes measure: Percentage of patients who demonstrate a reduction in office systolic BP of ≥ 5mmHg, ≥ 10 mmHg and ≥ 15 mmHg, secondaryOutcomes measure: Change in home and office heart rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06297278, orgStudyIdInfo id: IRB-23-01-5444, secondaryIdInfos id: R01MH132830, type: NIH, link: https://reporter.nih.gov/quickSearch/R01MH132830, briefTitle: Exercise Facilitation of Adolescent Fear Extinction, Frontolimbic Circuitry, and Endocannabinoids, acronym: BRAINS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-04-30, completionDateStruct date: 2028-04-30, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Wayne State University, class: OTHER, collaborators name: National Institute of Mental Health (NIMH), descriptionModule briefSummary: Anxiety disorders commonly begin during adolescence, and are characterized by deficits in the ability to inhibit or extinguish pathological fear. Recent research has provided new understanding of how fear is learned and can be regulated in the adolescent brain, and how the endocannabinoid system shapes these processes; however, these advances have not yet translated into improved therapeutic outcomes for adolescents with anxiety. This study will test whether a behavioral intervention, acute exercise, can help to improve fear regulation by enhancing brain activity and endocannabinoid signaling. This line of research may ultimately lead to more effect treatments for adolescent anxiety, and to new preventive strategies for at-risk youth., conditionsModule conditions: Adolescence, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 174, type: ESTIMATED, armsInterventionsModule interventions name: Moderate Intensity Exercise, outcomesModule primaryOutcomes measure: Skin Conductance Responding (SCR), primaryOutcomes measure: Unconditioned Stimulus (US) Expectancy Ratings, primaryOutcomes measure: Fear extinction neural circuitry: Functional activation and coupling, primaryOutcomes measure: Endocannabinoid (eCB) Concentrations, secondaryOutcomes measure: Fear Ratings, secondaryOutcomes measure: Approach/Avoidance Behavior, secondaryOutcomes measure: Amygdala response during extinction recall, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Tolan Park Medical Building, status: RECRUITING, city: Detroit, state: Michigan, zip: 48201, country: United States, contacts name: MacKenna Shampine, role: CONTACT, phone: 313-242-7464‬, email: mackenna.shampine@wayne.edu, geoPoint lat: 42.33143, lon: -83.04575, hasResults: False